K. G. Jebsen Center for Specific Autoimmune Therapy

The primary goal of the KG Jebsen Center for Specific Autoimmune Therapy is to establish approaches that enable specific reduction of the B cells that cause disease. The secondary goal of the center is to establish a powerhouse where clinicians and laboratory scientists interact daily, and which will facilitate the development of the knowledge and skills needed to establish, test, and critically evaluate new advanced therapeutic drugs for patients with autoimmune diseases.
B cells are a type of white blood cell that is crucial to the immune system. The cells are best known for making antibodies, but they also have an important function in interacting with T cells, another type of white blood cell. These two cell types work together to fight viruses and bacteria. People with autoimmune diseases have a defect in their immune system that causes it to attack its own cells and tissues, as if some cells in the body were a virus. It has been shown that removing all the B cells in the body can be an effective way to treat autoimmune diseases. By using a type of treatment developed for cancer therapy on patients with very severe autoimmune disease, the autoimmune attack on one’s own tissue has stopped and the disease in these patients has apparently been cured. One type of such treatment is specially made (i.e. genetically modified) T cells (CAR-T cells) that can track down and remove all B cells. Another way is to add molecules (so-called BiTE) to the body that allow normal T cells to remove all B cells. Promising results have also been achieved in animal experiments and in laboratory models using such treatment reagents with the aim of removing only the B cells that cause the disease. In such treatment, surgical warfare is carried out instead of carpet bombing. This has so far only been shown for autoimmune diseases where the molecules (autoantigens) the immune system attacks are on the surface of the body’s cells. For many autoimmune diseases, the autoantigens are inside the cells. In the preparation of reagents that remove B cells targeting autoantigens inside the cells, there is a cell biology problem. At the K.G. Jebsen Center for Specific Immunotherapy, we want to solve this problem so that we can create new types of advanced immunotherapy that will find and remove the B cells that are involved in the autoimmune attack in diseases where the autoantigens are found inside the cells. We will work with this approach within four autoimmune diseases: systemic sclerosis, antisynthetase syndrome, rheumatoid arthritis and celiac disease.
Immunologist and researcher at Oslo University Hospital (100%)
Rheumatologist and senior physician at Diakonhjemmet Hospital (50%), senior researcher (50%) and associate professor at the University of Oslo
Immunologist and associate professor at the University of Oslo (100%)
Gastroenterologist, internist and professor/senior physician at the University of Oslo (100%)/Oslo University Hospital (20%).
Rheumatologist. Professor at the University of Oslo (50%), physician and research leader at Oslo University Hospital (70%)
Rheumatologist/senior physician (50%) and postdoc (50%) at Oslo University Hospital
Immunologist and professor/senior physician at the University of Oslo (100%)/Oslo University Hospital (20%).
Media
- Krhono75 millioner kroner til tre nye forskningssentre21.01.2026
The Centre in brief
Leader: Ludvig M. Sollid
Start year: 2026
Host institution: University of Oslo
Funding from the foundation: 25 MNOK
Home page: – will come soon-
Contact information:
KG Jebsen Center for Specific Autoimmune Therapy
Universitetet i Oslo
Institutt for klinisk medisin
P.O.Box 4950 Nydalen
0424 Oslo
Norway
Scientific advisory board
- Professor Gabriel Victora, Rockefeller University
- Professor Rene Toes, Leiden University Medical Center
- Professor Vivianne Malmström, Karolinska Institutet
